[Toxic myopathies related to the administration of hypolipidemic agents: are the drugs the only things responsible?].
The characteristics are reported of five myopathies initially considered toxic in nature caused by the administration of blood lipid lowering agents. In three cases the final diagnosis was hypothyroidism, thus demonstrating the need to rule out the potential causes of secondary dyslipidemia before initiating therapy. Likewise, and because of the rare true muscle involvement from blood lipid lowering agents, it is necessary to investigate those diseases or factors enhancing muscle toxicity when it appears.
D000328:Adult; D000368:Aged; D001629:Bezafibrate / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced* / Q000175:diagnosis; D019821:Simvastatin
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D008148:Lovastatin; D019821:Simvastatin; D001629:Bezafibrate
Miopatías tóxicas en relación con la administración de hipolipidemiantes: son los fármacos los únicos responsables?